A trial of AZD4547 in combination with cisplatin and capecitabine
| ISRCTN | ISRCTN66171897 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN66171897 |
| Secondary identifying numbers | AZD4547-2011 |
- Submission date
- 14/12/2011
- Registration date
- 14/03/2012
- Last edited
- 24/11/2015
- Recruitment status
- Stopped
- Overall study status
- Stopped
- Condition category
- Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Contact information
Prof Jeff Evans
Scientific
Scientific
The Beastson West of Scotland Cancer Centre
University of Glasgow
1053 Great Western Road
Glasgow
G12 0YN
United Kingdom
| Phone | +44 (0)141 301 7116 |
|---|---|
| j.evans@beatson.gla.ac.uk |
Study information
| Study design | Multi-centre two stage trial |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Hospital |
| Study type | Treatment |
| Participant information sheet | Not available in web format, please use the contact details below to request a patient information sheet |
| Scientific title | A Phase I/II trial of AZD4547 in combination with cisplatin and capecitabine |
| Study acronym | FACING |
| Study objectives | Stage 1: 1. To identify a recommended dose of AZD4547 when administered in combination with Cisplatin and Capecitabine (CX) 2. To identify the DLT (Dose-Limiting Toxicity) of AZD4547 when administered in combination with Cisplatin and Capecitabine 2.1. To explore the safety and tolerability of AZD4547 when administered in combination with Cisplatin and Capecitabine 2.2. To determine the pharmacokinetic profile of AZD4547 when administered in combination with Cisplatin and Capecitabine 3. To investigate the use of biomarkers of predictive and pharmacodynamic effects of AZD4547 when administered in combination with Cisplatin and Capecitabine 3.1. To explore the anti-tumour efficacy of the combination of AZD4547 administered with Cisplatin and Capecitabine Stage 2: 1. To determine the effect of AZD4547 in combination with Cisplatin and Capecitabine (AZD4547-CX) compared with Cisplatin and Capecitabine (CX) and placebo on progression-free survival (PFS) when administered to patients with locally advanced or metastatic gastro-oesophageal adenocarcinoma and with FGFR2 polysomy or amplification (FISH > 4) 2. To compare the mean change in tumour size assessments from baseline after 9 weeks of treatment between the study arms 2.1. To compare objective overall (complete and partial) response rates in these patients treated with either AZD4547-CX or CX-placebo 2.2. To compare overall survival in these patients treated with either AZD4547-CX or CX-placebo 2.3. To compare PFS in the FISH 6 and FISH 4/5 sub-groups 2.4. To compare the effect of AZD4547 between the FISH 6 and the FISH 4/5 sub-groups 2.5. To further describe the safety and toxicity profiles of AZD4547-CX and CX-placebo in this patient population 3. To investigate the use of biomarkers of predictive and pharmacodynamic effects of AZD4547-CX and CX-placebo in these patients 3.1. To determine the incidence of FGFR2 polysomy or amplification in the UK population with locally advanced or metastatic gastro-oesophageal adenocarcinoma 3.2. To determine the association between changes in tumour size after 9 weeks of treatment and progression-free survival 3.3 To explore sparse population pharmacokinetics in a subset of patients |
| Ethics approval(s) | West of Scotland Research Ethics Committee, 18 October 2011, ref: 11/WS/0039 |
| Health condition(s) or problem(s) studied | Cancer |
| Intervention | Stage 1 AZD4547 will be administered orally twice daily in equally divided doses at 12-hourly intervals in a days 1-14 3-weekly administration schedule. The starting dose of AZD4547 will be 40mgs at 12 hourly intervals in a day 1-14 3-weekly scheduled based upon emerging safety and tolerability data, and it will be administered in combination with cisplatin and capecitabine. Cisplatin will be administered at a dose of 80 mg/m2 intravenously 3-weekly, and capecitabine will be administered orally twice daily in equally divided doses (1000 mg/m2 bid) on days 1 C 14 of each 3-weekly cycle. The number of tablets of capecitabine to be administered based on body surface area (BSA). Stage 2 Patients who are recruited into the Stage 2 part of the study will receive either AZD4547-CX, consisting of AZD4547 orally at the recommended dose (as determined in the Phase I part of the study) in combination with cisplatin (80 mg/m2 intravenously 3-weekly) and capecitabine (1000 mg/m2 bid orally days 1 C 14 of each 3-weekly cycle) or CX, consisting of cisplatin (80 mg/m2 intravenously 3-weekly) and capecitabine (1000 mg/m2 bid orally days 1 ¨C 14 of each 3-weekly cycle) plus placebo at 12 hourly intervals in a days 1-14 3-weekly schedule. |
| Intervention type | Other |
| Primary outcome measure | Stage 1: Toxicity, with determination of the safety, toxicity, dose-limiting toxicity and the recommended dose of AZD4547 when administered orally in a twice daily days 1-14 3-weekly schedule in combination with Cisplatin and Capecitabine, administered three-weekly, based on clinical and laboratory toxicity. Stage 2: T Progression-free survival. |
| Secondary outcome measures | Stage 1: The pharmacokinetic profile of AZD4547 when administered in this combination and tertiary (exploratory) endpoints which include anti-tumour activity of the combination and the use of biomarkers for prediction and pharmacodynamic effects of AZD4547 when administered in this combination. Stage 2: Mean tumour size assessments after 9 weeks of therapy, objective response, safety and tolerability of the treatment regimens, differential effect of AZD4547 in FISH 4/5 and FISH6 subgroups, progression free survival in the FISH6 subgroup and overall survival. The tertiary (exploratory) endpoints will include the use of biomarkers for predictive and pharmacodynamic effects of AZD4547 in these patients, the incidence of FGFR2 polysomy or amplification in the UK population of patients with gastro-oesophageal adenocarcinoma, and sparse population pharmacokinetics. |
| Overall study start date | 15/01/2012 |
| Completion date | 15/12/2015 |
| Reason abandoned (if study stopped) | Participant recruitment issue |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Sex | Both |
| Target number of participants | 18 patients in Stage 1 and 140 patients in Stage 2 |
| Key inclusion criteria | 1. Male or female and over 25 years of age 2. Eastern Cooperative Oncology Group (ECOG) performance status 0, or 1 3. Written informed consent 4. No chemotherapy, hormonal therapy, immunotherapy, targeted systemic cancer therapy, or investigational therapy within 4 weeks of study entry (6 weeks for mitomycin C and nitrosureas) 5. No radiotherapy within 4 weeks of study entry. 6. Adequate haematological function, as follows: 6.1. Haemoglobin > 10g/dl 6.2. Neutrophils > 1.5 x 109/l 6.3. Platelets > 100 x 109/l 7. Adequate biochemical function, as follows: 7.1. Bilirubin < 1.5 x ULN (Upper Limit of Normal) 7.2. ALT or AST < 2.5 x ULN 7.3. Alkaline Phosphatase < 2.5 x ULN 7.4. Serum Phosphate < ULN 7.5. Serum Calcium < ULN 7.6. Serum Magnesium < ULN 8. Adequate renal function with creatinine clearance / glomerular filtration rate > 60 mls/min. If the creatinine clearance / glomerular filtration rate is less than 60 mls/min as calculated by the Cockroft-Gault formula, then the creatinine clearance / glomerular filtration rate should be measured by either a radio-isotope technique or by 24-hour urine collection 9. Life expectancy >12 weeks 10. Able to reliably tolerate and comply with oral medication Additional stage 1 inclusion criteria: 1. Histologically or cytologically proven advanced solid tumour that is refractory to standard therapies, or for whom no standard therapies exist, or for whom cisplatin and capecitabine is an acceptable treatment option 2. No concomitant use of another anti-cancer therapy with the exception of patients with prostate cancer who are on a LHRH analogue who can continue this during the study 3. Disease which is either measurable (RECIST 1.1) or evaluable Additional stage 2 inclusion criteria: 1. Histologically or cytologically proven adenocarcinoma or undifferentiated carcinoma of the oesophagus, gastro-oesophageal junction, or stomach 2. Locally advanced (inoperable) disease (that is not suitable for a combined chemo-radiation approach for tumours confined to the lower oesophagus) or metastatic disease 3. Tumours with FGFR2 polysomy or amplification (FISH 4/5 or FISH 6) 4. No prior neo-adjuvant or adjuvant chemotherapy, and no prior chemotherapy for advanced disease 5. No concomitant use of another anti-cancer therapy during the study 6. At least one bi-dimensional measurable lesion as defined by RECIST 1.1 |
| Key exclusion criteria | 1. History of physical or psychiatric disorder that would prevent informed consent and compliance 2. Pregnant or lactating women 3. Fertile woman of childbearing potential not willing to use adequate contraception (oral contraceptives, intrauterine device or barrier method of contraception in conjunction with spermicidal jelly or surgically sterile) for the study duration and at least six months afterwards. It is not known whether AZD4547 can induce hepatic enzymes. If oral contraception is used, it is recommended that this is used in combination with a barrier method as well. Fertile men who are not willing to use a barrier method of contraception (condoms with spermicidal jelly). Fertile men should also refrain from donating sperm from the start of dosing until 16 weeks after discontinuing study treatment. Male patients wishing to subsequently father children should attend for freezing of sperm samples prior to dosing. 4. Evidence of uncontrolled infection (defined as infection that cannot be resolved readily with antibiotics prior to patient entry into the trial) 5. Major surgery within 28 days prior to study entry or anticipated to occur while on study 6. Prolonged QTc (corrected) interval of > 470ms on ECG or a family history of long QT syndrome 7. History of active or treated brain metastases (with the exception of patients with resected brain metastases and no evidence of recurrence on CT or MRI of the brain) 8. CNS disease (uncontrolled seizures or cerebrovascular accident/transient ischaemic attack /subarachnoid haemorrhage within 6 months) 9. Any unresolved toxicity CTC Grade 1 from previous systemic anti-cancer therapy except alopecia 10. Pre-existing sensory or motor neuropathy ¡Ý grade 1 11. Known hypersensitivity to cisplatin 12. Known DPD deficiency or hypersensitivity to capecitabine 13. Known hypersensitivity to AZD4547 14. History of significant cardiac disease including myocardial infarction within the previous 6 months, uncontrolled ischaemic heart disease, second or third degree heart block, any other persistent or intermittent cardiac arrhythmia requiring medication, congestive cardiac failure > NYHA Grade 2 (Appendix 3), or left ventricular ejection fraction of < 50% 15. Patients with a lack of physical integrity of the GI tract leading to a malabsorption syndrome or intestinal obstruction 16. Evidence of any other disease, metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contra-indicates the use of an investigational drug or puts the patient at high risk for treatment-related complications 17. Patients with significant hearing loss such that Cisplatin is contra-indicated 18. Patients taking CYP3A4 and CYP2D6 inducers or inhibitors 19. Current evidence or previous history of retinal pigmented epithelium detachment (RPED) 20. Previous laser treatment or intra-ocular injection for treatment of macular degeneration 21. Current evidence or previous history of dry or wet age-related macular degeneration 22. Current evidence or previous history of retinal vein occlusion (RVO) 23. Current evidence or previous history of retinal degenerative diseases (e.g. hereditary) 24. Current evidence or previous history of any other clinically relevant chorioretinal defect Additional Stage 2 exclusion criteria: History of prior malignancy within the last 5 years other than patients with basal cell carcinoma of the skin or in situ neoplasia of the cervix uteri who have undergone potentially curative treatment |
| Date of first enrolment | 15/01/2012 |
| Date of final enrolment | 15/12/2015 |
Locations
Countries of recruitment
- Scotland
- United Kingdom
Study participating centre
The Beastson West of Scotland Cancer Centre
Glasgow
G12 0YN
United Kingdom
G12 0YN
United Kingdom
Sponsor information
NHS Greater Glasgow and Clyde (UK)
Hospital/treatment centre
Hospital/treatment centre
c/o Nathaniel Brittain
Academic Research Co-ordinator
Research and Development Department
Tennent Institute
Western Infirmary
Dumbarton Road
Glasgow
G11 6NT
Scotland
United Kingdom
| Phone | +44 (0)141 211 8544 |
|---|---|
| nathaniel.brittain@ggc.scot.nhs.uk | |
| Website | http://www.nhsggc.org.uk/ |
"ROR" |
https://ror.org/05kdz4d87 |
Funders
Funder type
Charity
Cancer Research (UK) ref: C2193/A12946
No information available
AstraZeneca (UK) ref: D2610C00010
Government organisation / For-profit companies (industry)
Government organisation / For-profit companies (industry)
- Alternative name(s)
- AstraZeneca PLC, Pearl Therapeutics
- Location
- United Kingdom
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| HRA research summary | 28/06/2023 | No | No |
Editorial Notes
24/11/2015: The study closed early due to concerns regarding patient selection, based on FISH testing for FGFR status, which was crucial to patient screening and eligibility for study entry. All efforts were made to set up an academic collaboration to perform FISH testing however it became apparent that setting up timelines for this were a limiting factor. Therefore a mutual decision was taken between AstraZeneca and the Co-Sponsors to close the study early to recruitment.
